Literature DB >> 15860471

Randomized controlled drug trials on very elderly subjects: descriptive and methodological analysis of trials published between 1990 and 2002 and comparison with trials on adults.

Jean-Laurent Le Quintrec1, Caroline Bussy, Jean-Louis Golmard, Christian Hervé, Alain Baulon, François Piette.   

Abstract

BACKGROUND: Very elderly subjects (VES; aged 80 years or older) constitute a special population as they frequently present multiple diseases (polypathology). Results from trials on general adult populations therefore cannot be extrapolated to VES. We performed a census of randomized controlled trials (RCT) on VES published between 1990 and 2002, and carried out a descriptive and methodological analysis of these RCT/VES, comparing them with matched RCT on general adult populations (control RCT, RCT/C).
METHODS: We searched for RCT/VES in two international databases (EMBASE and MEDLINE) and then manually. RCT/C were matched to RCT/VES for disease area and year of publication. The methodological quality of each RCT was assessed with Chalmers' scale.
RESULTS: We identified 84 RCT/VES, 63 of which were conclusive and 21, inconclusive. Subjects were institutionalized in 48 RCT, and community dwelling in 11 RCT (unspecified in 25 RCT). Efficacy was the main criterion in 75 RCT; tolerance in 9 RCT. Twenty-six RCT were published by geriatrics journals, and 58 by general medical journals. The RCT/VES covered most of the disease areas of geriatrics. The 84 RCT/VES had a mean methodological quality score of 0.578 +/- 0.157. The matched 84 RCT/C had a mean methodological quality score of 0.592 +/- 0.116 (p = .466). The methodological quality score of RCT/VES increased with the number of included subjects (p = .004) and the year of publication (p = .001).
CONCLUSIONS: The methodological quality of RCT/VES is equivalent to that of RCT in general adult populations. Nevertheless, RCT/VES remain very scarce, and neglect certain diseases. RCT/VES and the inclusion of very elderly subjects in RCT on adults should be strongly encouraged.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15860471     DOI: 10.1093/gerona/60.3.340

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  10 in total

1.  Functional outcomes for clinical trials in frail older persons: time to be moving.

Authors: 
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2008-02       Impact factor: 6.053

2.  The Geriatric Minimum Data Set for clinical trials (GMDS).

Authors:  G Abellan Van Kan; A Sinclair; S Andrieu; M Olde Rikkert; G Gambassi; B Vellas
Journal:  J Nutr Health Aging       Date:  2008-03       Impact factor: 4.075

3.  Exclusion of older people from clinical trials: professional views from nine European countries participating in the PREDICT study.

Authors:  Peter Crome; Frank Lally; Antonio Cherubini; Joaquim Oristrell; Andrew D Beswick; A Mark Clarfield; Cees Hertogh; Vita Lesauskaite; Gabriel I Prada; Katarzyna Szczerbińska; Eva Topinkova; Judith Sinclair-Cohen; David Edbrooke; Gary Mills
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 4.  Treatment considerations for elderly and frail patients with neuropathic pain.

Authors:  Kenneth E Schmader; Ralf Baron; Maija L Haanpää; John Mayer; Alec B O'Connor; Andrew S C Rice; Brett Stacey
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

5.  [Elderly patients in clinical trials: new fitness-adapted concepts].

Authors:  V Goede; M Hallek
Journal:  Internist (Berl)       Date:  2007-11       Impact factor: 0.743

6.  Use of health services and medicines amongst Australian war veterans: a comparison of young elderly, near centenarians and centenarians.

Authors:  Elizabeth E Roughead; Lisa M Kalisch; Emmae N Ramsay; Philip Ryan; Andrew L Gilbert
Journal:  BMC Geriatr       Date:  2010-11-04       Impact factor: 3.921

7.  Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs.

Authors:  Cécile Konrat; Isabelle Boutron; Ludovic Trinquart; Guy-Robert Auleley; Philippe Ricordeau; Philippe Ravaud
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

Review 8.  Handling of informed consent and patient inclusion in research with geriatric trauma patients - a matter of protection or disrespect?

Authors:  Jana S Jensen; Stella Reiter-Theil; Diana A Celio; Marcel Jakob; Werner Vach; Franziska J Saxer
Journal:  Clin Interv Aging       Date:  2019-02-13       Impact factor: 4.458

Review 9.  Risk assessment for cancer surgery in elderly patients.

Authors:  Hodigere S J Ramesh; Tom Boase; Riccardo A Audisio
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

Review 10.  Neuromuscular blockade in the elderly patient.

Authors:  Luis A Lee; Vassilis Athanassoglou; Jaideep J Pandit
Journal:  J Pain Res       Date:  2016-06-17       Impact factor: 3.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.